Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Combined With CD19-CAR T Cells in Relapsed/Refractory B-NHL
NCT06464185Phase 2Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2024
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, CD19-CAR-T cells in B-cell non-Hodgkin lymphoma, sponsored by Institute of Hematology and Blood Diseases Hospital. Started May 2024; status: active, not recruiting.
02
Drugs
glofitamabCD19-CAR-T cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06464185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06464185.